Trial Profile
A Randomized, Open-Label Study of Lopinavir/Ritonavir 400/100 mg Tablet Twice Daily + Co-Formulated Emtricitabine/Tenofovir Disoproxil Fumarate 200/300 mg Once Daily Versus Lopinavir/Ritonavir 400/100 mg Tablet Twice Daily + Raltegravir 400 mg Twice Daily in Antiretroviral Naive, HIV-1 Infected Subjects
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Lopinavir/ritonavir (Primary) ; Emtricitabine/tenofovir disoproxil fumarate; Raltegravir
- Indications HIV-1 infections
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms PROGRESS
- 13 Feb 2012 Additional location (Poland) added as reported by ClinicalTrials.gov.
- 23 Oct 2011 Results presented at the 49th Annual Meeting of the Infectious Diseases Society of America.
- 15 Oct 2011 Health-related quality of life results presented at the 13th European AIDS Conference.